Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALGS NASDAQ:ALVR NASDAQ:CGEM NASDAQ:FMTX NASDAQ:OCGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALGSAligos Therapeutics$10.44+4.5%$9.92$3.76▼$46.80$64.21M2.77152,554 shs72,809 shsALVRAlloVir$4.63-3.3%$4.33$7.96▼$24.15$23.35M0.6315,685 shs81,005 shsCGEMCullinan Therapeutics$8.56+8.9%$6.98$5.68▼$17.50$505.64M-0.12544,512 shs1.45 million shsFMTXForma Therapeutics$20.01$20.00$4.95▼$20.68$957.54M-0.94847,595 shs1 shsOCGNOcugen$1.62+1.3%$1.32$0.52▼$1.90$473.53M4.24.70 million shs2.52 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALGSAligos Therapeutics0.00%+5.94%+3.31%+15.63%+37.79%ALVRAlloVir0.00%+4.04%+5.47%+93.72%-73.96%CGEMCullinan Therapeutics0.00%+6.22%+26.77%+4.52%-53.13%FMTXForma Therapeutics0.00%0.00%0.00%0.00%0.00%OCGNOcugen0.00%-6.43%+19.40%+58.42%+70.21%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALGSAligos Therapeutics$10.44+4.5%$9.92$3.76▼$46.80$64.21M2.77152,554 shs72,809 shsALVRAlloVir$4.63-3.3%$4.33$7.96▼$24.15$23.35M0.6315,685 shs81,005 shsCGEMCullinan Therapeutics$8.56+8.9%$6.98$5.68▼$17.50$505.64M-0.12544,512 shs1.45 million shsFMTXForma Therapeutics$20.01$20.00$4.95▼$20.68$957.54M-0.94847,595 shs1 shsOCGNOcugen$1.62+1.3%$1.32$0.52▼$1.90$473.53M4.24.70 million shs2.52 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALGSAligos Therapeutics0.00%+5.94%+3.31%+15.63%+37.79%ALVRAlloVir0.00%+4.04%+5.47%+93.72%-73.96%CGEMCullinan Therapeutics0.00%+6.22%+26.77%+4.52%-53.13%FMTXForma Therapeutics0.00%0.00%0.00%0.00%0.00%OCGNOcugen0.00%-6.43%+19.40%+58.42%+70.21%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALGSAligos Therapeutics 2.00Hold$50.00378.93% UpsideALVRAlloVir 0.00N/AN/AN/ACGEMCullinan Therapeutics 2.57Moderate Buy$26.00203.74% UpsideFMTXForma Therapeutics 0.00N/AN/AN/AOCGNOcugen 2.33Hold$7.00332.10% UpsideCurrent Analyst Ratings BreakdownLatest OCGN, FMTX, CGEM, ALVR, and ALGS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025ALGSAligos TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025CGEMCullinan TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025OCGNOcugenWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025ALGSAligos TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025CGEMCullinan TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025OCGNOcugenWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/19/2025OCGNOcugenChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.009/16/2025CGEMCullinan TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold9/12/2025ALGSAligos TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$50.009/12/2025CGEMCullinan TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.009/10/2025CGEMCullinan TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$32.00(Data available from 10/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALGSAligos Therapeutics$3.94M16.30N/AN/A($7.50) per share-1.39ALVRAlloVirN/AN/AN/AN/A$29.35 per shareN/ACGEMCullinan TherapeuticsN/AN/AN/AN/A$10.14 per shareN/AFMTXForma Therapeutics$100.56M9.52N/AN/A$10.51 per share1.90OCGNOcugen$4.05M116.92N/AN/A$0.10 per share16.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALGSAligos Therapeutics-$131.21M-$19.79N/AN/AN/A-2,337.24%-22.41%-12.09%11/5/2025 (Estimated)ALVRAlloVir-$190.42M-$20.23N/A∞N/AN/A-71.03%-61.27%11/10/2025 (Estimated)CGEMCullinan Therapeutics-$167.38M-$3.23N/AN/AN/AN/A-36.56%-34.82%11/6/2025 (Estimated)FMTXForma Therapeutics-$172.96M-$4.00N/AN/AN/AN/A-39.68%-35.33%N/AOCGNOcugen-$54.05M-$0.20N/AN/AN/A-1,197.71%-255.25%-86.79%11/13/2025 (Estimated)Latest OCGN, FMTX, CGEM, ALVR, and ALGS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025OCGNOcugen-$0.06N/AN/AN/AN/AN/A11/6/2025Q3 2025CGEMCullinan Therapeutics-$0.95N/AN/AN/AN/AN/A11/5/2025Q3 2025ALGSAligos Therapeutics-$2.09N/AN/AN/A$0.50 millionN/A8/7/2025Q2 2025CGEMCullinan Therapeutics-$0.83-$1.07-$0.24-$1.07N/AN/A8/6/2025Q2 2025ALGSAligos Therapeutics-$2.35-$1.53+$0.82-$1.53$0.43 million$0.97 million8/1/2025Q2 2025OCGNOcugen-$0.06-$0.05+$0.01-$0.05$0.35 million$1.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALGSAligos TherapeuticsN/AN/AN/AN/AN/AALVRAlloVirN/AN/AN/AN/AN/ACGEMCullinan TherapeuticsN/AN/AN/AN/AN/AFMTXForma TherapeuticsN/AN/AN/AN/AN/AOCGNOcugenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALGSAligos TherapeuticsN/A6.316.31ALVRAlloVirN/A86.7886.78CGEMCullinan TherapeuticsN/A9.839.83FMTXForma TherapeuticsN/A12.7412.74OCGNOcugen9.181.831.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALGSAligos Therapeutics60.43%ALVRAlloVir66.05%CGEMCullinan Therapeutics86.31%FMTXForma Therapeutics87.39%OCGNOcugen10.27%Insider OwnershipCompanyInsider OwnershipALGSAligos Therapeutics4.80%ALVRAlloVir32.07%CGEMCullinan Therapeutics6.07%FMTXForma Therapeutics5.79%OCGNOcugen4.29%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALGSAligos Therapeutics906.15 million5.86 millionNo DataALVRAlloVir1105.04 million3.43 millionOptionableCGEMCullinan Therapeutics3059.07 million55.49 millionOptionableFMTXForma Therapeutics16647.85 million45.08 millionNot OptionableOCGNOcugen80292.30 million279.77 millionOptionableOCGN, FMTX, CGEM, ALVR, and ALGS HeadlinesRecent News About These CompaniesOcugen (NASDAQ:OCGN) Shares Down 7.4% - Should You Sell?October 11, 2025 | marketbeat.comWeiss Ratings Reaffirms Sell (E+) Rating for Ocugen (NASDAQ:OCGN)October 10, 2025 | marketbeat.comOcugen to Highlight Gene Therapy Pipeline at Key Industry and Investor ConferencesOctober 6, 2025 | msn.comOcugen (NASDAQ:OCGN) Hits New 52-Week High - Here's WhyOctober 3, 2025 | marketbeat.comOcugen to Present at Industry and Investor Conferences in October 2025October 2, 2025 | markets.businessinsider.comOcugen to Present at Major Biotechnology Conferences Focused on Advancements in Gene Therapies for Blindness DiseasesOctober 2, 2025 | quiverquant.comQTraders Buy High Volume of Ocugen Call Options (NASDAQ:OCGN)October 1, 2025 | marketbeat.comGoldman Sachs Group Inc. Lowers Holdings in Ocugen, Inc. $OCGNSeptember 27, 2025 | marketbeat.comOcugen (NASDAQ:OCGN) Reaches New 52-Week High - Time to Buy?September 24, 2025 | marketbeat.comOcugen: A Retinal Disease Juggernaut In The MakingSeptember 23, 2025 | seekingalpha.comOcugen (NASDAQ:OCGN) Earns Buy Rating from Chardan CapitalSeptember 20, 2025 | marketbeat.com200,100 Shares in Ocugen, Inc. $OCGN Purchased by Procyon Advisors LLCSeptember 20, 2025 | marketbeat.comOcugen Strikes $187.5 Million Licensing Deal With Kwangdong for Gene Therapy in KoreaSeptember 20, 2025 | msn.comOcugen (NASDAQ:OCGN) Upgraded by Wall Street Zen to Hold RatingSeptember 20, 2025 | marketbeat.comForecasting The Future: 4 Analyst Projections For OcugenSeptember 19, 2025 | benzinga.comOcugen (OCGN): Evaluating Valuation Following Exclusive Korean Licensing Deal for Gene Therapy OCU400September 18, 2025 | finance.yahoo.comWhy Ocugen (OCGN) Is Up 16.5% After Licensing OCU400 Gene Therapy Rights to KwangdongSeptember 16, 2025 | finance.yahoo.comOcugen Signs Exclusive License Agreement with KwangdongSeptember 16, 2025 | tipranks.comOcugen executes licensing agreement with Kwangdong PharmaceuticalSeptember 15, 2025 | msn.comOcugen, Inc. Announces Licensing Agreement with Kwangdong Pharmaceutical for OCU400, Potentially Worth Up to $187.5 MillionSeptember 15, 2025 | quiverquant.comQOcugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in KoreaSeptember 15, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOCGN, FMTX, CGEM, ALVR, and ALGS Company DescriptionsAligos Therapeutics NASDAQ:ALGS$10.44 +0.45 (+4.50%) Closing price 04:00 PM EasternExtended Trading$10.20 -0.24 (-2.35%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.AlloVir NASDAQ:ALVR$4.63 -0.16 (-3.34%) As of 10/17/2025AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.Cullinan Therapeutics NASDAQ:CGEM$8.56 +0.70 (+8.91%) Closing price 04:00 PM EasternExtended Trading$8.62 +0.06 (+0.70%) As of 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Forma Therapeutics NASDAQ:FMTXForma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.Ocugen NASDAQ:OCGN$1.62 +0.02 (+1.25%) Closing price 04:00 PM EasternExtended Trading$1.62 0.00 (0.00%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner JPMorgan Crushes Q3; But Is the Steady Eddy Stock Hitting A Wall? Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
